Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PPP1CC_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PPP1CC_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPP1CC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPP1CC_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PPP1CC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PPP1CC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PPP1CC_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PPP1CC_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005076711 | Prostate | Tumor | regulation of neurogenesis | 93/3246 | 364/18723 | 4.45e-05 | 5.02e-04 | 93 |
GO:004275214 | Prostate | Tumor | regulation of circadian rhythm | 39/3246 | 121/18723 | 4.69e-05 | 5.21e-04 | 39 |
GO:000931415 | Prostate | Tumor | response to radiation | 109/3246 | 456/18723 | 1.94e-04 | 1.70e-03 | 109 |
GO:005196211 | Prostate | Tumor | positive regulation of nervous system development | 69/3246 | 272/18723 | 4.99e-04 | 3.67e-03 | 69 |
GO:001631113 | Prostate | Tumor | dephosphorylation | 98/3246 | 417/18723 | 7.31e-04 | 5.08e-03 | 98 |
GO:005196011 | Prostate | Tumor | regulation of nervous system development | 102/3246 | 443/18723 | 1.20e-03 | 7.60e-03 | 102 |
GO:004206312 | Prostate | Tumor | gliogenesis | 73/3246 | 301/18723 | 1.35e-03 | 8.46e-03 | 73 |
GO:004426212 | Prostate | Tumor | cellular carbohydrate metabolic process | 66/3246 | 283/18723 | 5.90e-03 | 2.74e-02 | 66 |
GO:00096491 | Prostate | Tumor | entrainment of circadian clock | 12/3246 | 34/18723 | 9.19e-03 | 3.95e-02 | 12 |
GO:000691324 | Skin | cSCC | nucleocytoplasmic transport | 162/4864 | 301/18723 | 4.20e-25 | 1.10e-22 | 162 |
GO:005116924 | Skin | cSCC | nuclear transport | 162/4864 | 301/18723 | 4.20e-25 | 1.10e-22 | 162 |
GO:0006091111 | Skin | cSCC | generation of precursor metabolites and energy | 224/4864 | 490/18723 | 1.13e-21 | 2.21e-19 | 224 |
GO:001598026 | Skin | cSCC | energy derivation by oxidation of organic compounds | 154/4864 | 318/18723 | 4.19e-18 | 5.15e-16 | 154 |
GO:0032386110 | Skin | cSCC | regulation of intracellular transport | 156/4864 | 337/18723 | 4.48e-16 | 3.96e-14 | 156 |
GO:0046822111 | Skin | cSCC | regulation of nucleocytoplasmic transport | 59/4864 | 106/18723 | 8.03e-11 | 3.68e-09 | 59 |
GO:000762323 | Skin | cSCC | circadian rhythm | 89/4864 | 210/18723 | 1.55e-07 | 3.51e-06 | 89 |
GO:000647024 | Skin | cSCC | protein dephosphorylation | 111/4864 | 281/18723 | 4.10e-07 | 7.96e-06 | 111 |
GO:000931424 | Skin | cSCC | response to radiation | 166/4864 | 456/18723 | 4.37e-07 | 8.41e-06 | 166 |
GO:003292222 | Skin | cSCC | circadian regulation of gene expression | 37/4864 | 68/18723 | 5.65e-07 | 1.08e-05 | 37 |
GO:004851123 | Skin | cSCC | rhythmic process | 110/4864 | 298/18723 | 1.83e-05 | 2.19e-04 | 110 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP1CC | SNV | Missense_Mutation | novel | c.452N>G | p.Thr151Ser | p.T151S | P36873 | protein_coding | deleterious_low_confidence(0.02) | benign(0.01) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
PPP1CC | SNV | Missense_Mutation | novel | c.365G>A | p.Arg122Lys | p.R122K | P36873 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.967) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PPP1CC | SNV | Missense_Mutation | | c.493N>A | p.Val165Met | p.V165M | P36873 | protein_coding | tolerated_low_confidence(0.07) | benign(0.332) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
PPP1CC | SNV | Missense_Mutation | | c.348N>T | p.Glu116Asp | p.E116D | P36873 | protein_coding | tolerated_low_confidence(0.17) | benign(0.003) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PPP1CC | SNV | Missense_Mutation | novel | c.308C>T | p.Thr103Met | p.T103M | P36873 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.951) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1CC | SNV | Missense_Mutation | | c.28G>A | p.Asp10Asn | p.D10N | P36873 | protein_coding | tolerated_low_confidence(0.07) | benign(0.078) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PPP1CC | SNV | Missense_Mutation | | c.902A>C | p.Lys301Thr | p.K301T | P36873 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.662) | TCGA-QG-A5YV-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | CR |
PPP1CC | SNV | Missense_Mutation | novel | c.610N>A | p.Leu204Ile | p.L204I | P36873 | protein_coding | deleterious_low_confidence(0.03) | benign(0.373) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PPP1CC | SNV | Missense_Mutation | novel | c.941G>T | p.Arg314Met | p.R314M | P36873 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.802) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1CC | SNV | Missense_Mutation | novel | c.268N>A | p.Leu90Ile | p.L90I | P36873 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.87) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |